News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    

Clinical - Phase I
Michael Meyers, M.D., Ph.D., Joins Syndax As SVP And Chief Development Officer 9/1/2015
Blueprint Medicines (BPMC) To Present Preclinical Data On BLU-554 And On Novel Drug Target At International Liver Cancer Association 9th Annual Conference 9/1/2015
Replicel Life Sciences Cleared To Initiate Clinical Trial Of RCS-01 For Dermal Rejuvenation 9/1/2015
Xbiotech Advances Phase I/II Clinical Study Of Novel True Human Therapeutic Antibody For Treating Serious Infections Due To Staphylococcus Aureus 9/1/2015
RedHill Biopharma Ltd. (RDHL) Announces Last Patient Visit In The Phase I Study With YELIVA (ABC294640) For Advanced Solid Tumors 9/1/2015
Heat Biologics Announces Clinical Trial Combining HS-110 And PD-1 Checkpoint Inhibitor In NSCLC 9/1/2015
BioTime (BTX) Chief Executive Officer Dr. Michael D. West To Be Keynote Speaker At Stem Cells & Regenerative Medicine Congress 2015 9/1/2015
Adaptimmune Expands Trial Of T-Cell Therapy For Synovial Sarcoma And Achieves Clinical Milestones 9/1/2015
Alnylam (ALNY) And The Medicines Company (MDCO) Release: ALN-PCSsc Achieves Quarterly And Potentially Bi-Annual Subcutaneous Dose Regimen Profile For Effective LDL-C Lowering In Phase I Clinical Study 8/31/2015
Alnylam (ALNY), The Medicines Company (MDCO)'s Long-Acting Cholesterol Drug May Threaten Amgen (AMGN), Regeneron (REGN)-Sanofi (SNY)'s Blockbusters 8/31/2015
Asterias Biotherapeutics Concludes Recruitment Of Initial Safety Cohort Of The SCiStar Phase 1/2a Dose-Escalation Clinical Trial Of AST-OPC1 For Complete Cervical Spinal Cord Injury 8/31/2015
FLX Bio Announces Senior Management Hires And Initiation Of Phase 1 Trial Of FLX925 8/31/2015
Bionomics Limited (BNO.AX) Release: Successful BNC101 IND Submission Paves Way For Development Of Promising Cancer Stem Cell Drug Candidate 8/31/2015
Regen BioPharma Develops BORIS Gene Silencing Based Treatment For Unresectable Liver Cancer 8/31/2015
RXi Pharmaceuticals (RXII) Announces Advancements In Its Ophthalmology Clinical Program With RXI-109 8/31/2015
Portage Biotech's PPL Will Advance Its Lead Candidate PPL-003 To An IND For Dry Eye Disease And Uveitis 8/31/2015
Novogen Limited (NVGN) Announces The Outcome Of A Comprehensive Science Review 8/31/2015
Epizyme (EPZM) To Present At Upcoming Events In September 8/31/2015
MabVax Therapeutics, Inc. HuMab 5B1 Antibody Is Highlighted At Upcoming World Molecular Imaging Congress In Five Separate Presentations 8/31/2015
Alnylam (ALNY) Release: ALN-PCSsc Achieves Quarterly And Potentially Bi-Annual Subcutaneous Dose Regimen Profile For Effective LDL-C Lowering In Phase 1 Clinical Study 8/31/2015
DURECT Corporation (DRRX) To Participate In Upcoming Healthcare Conferences 8/28/2015
AGTC (AGTC) Announces Achievement Of XLRS Patient Enrollment Milestone In Biogen (BIIB) Collaboration 8/27/2015
Asterias Biotherapeutics To Present At Upcoming Investor Conferences 8/27/2015
Genmab A/S (GEN.CO) Release: Data Published In The New England Journal of Medicine Shows Daratumumab Monotherapy Induced Durable Responses In Heavily Pre-Treated Relapsed Or Refractory Multiple Myeloma Patients 8/27/2015
Notch3 Biomarker Results And Updated Data From OncoMed Pharmaceuticals, Inc. (OMED)'s Phase Ib/II PINNACLE Clinical Trial Accepted For Presentation At The 16th World Conference On Lung Cancer 8/27/2015
Portage Biotech's Biohaven Doses First Human Subject In Phase 1 Trial With Lead Drug Candidate BHV-0223 8/27/2015
ORYZON To Present At Rodman & Renshaw 17th Annual Global Investment Conference 8/27/2015
HUYA Bioscience International Sponsors Japan Society Of HTLV-1 Annual Meeting 8/27/2015
Summit Therapeutics Reports Financial Results For The Second Quarter Ended 31 July 2015 And Operational Progress 8/27/2015
Antibe Therapeutics Inc. (ATE.V) Reports Q1 2016 Interim Financial And Operating Results And A Further Update On Its Validation Studies 8/27/2015
Adocia And Eli Lilly (LLY) Initiate New Phase 1b Study Of Repeated Administration Of Ultra-Rapid Biochaperone Lispro In Patients With Type 1 Diabetes 8/27/2015
Nordic Nanovector: Results For The Second Quarter And Half Year 2015 8/26/2015
Verastem, Inc. (VSTM) To Present Data At The 16th World Conference On Lung Cancer 8/26/2015
Chrono Therapeutics, Inc. Receives Second Fast Track SBIR Grant From National Cancer Institute For Patient-Individualized Smoking Cessation Therapy 8/25/2015
Regulus (RGLS) Appoints Michael Huang, M.D. As Vice President, Clinical Development 8/25/2015
Corium International, Inc. Initiates Phase I Clinical Trial Of Corplex Donepezil Transdermal System For The Treatment Of Alzheimer's Disease 8/25/2015
Regen BioPharma BORIS Gene Silencing Technology Successfully Utilized By Independent Researchers To Kill Breast Cancer And Colon Cancer Stem Cells 8/24/2015
Cardiome Pharma Corp. (COM.TO) Expands Partnership With Eddingpharm (Cayman) Inc. To Commercialize AGGRASTAT In China 8/24/2015
OncoSec Medical Inc. Promotes Sheela Mohan-Peterson To Chief Legal And Compliance Officer 8/24/2015
MTG Biotherapeutics Announces That MTG-201 Was Granted Orphan Drug Designation By The US FDA For The Treatment Of Malignant Mesothelioma 8/24/2015
DelMar Pharmaceuticals To Present VAL-083 Lung Cancer Clinical Strategy At The 16th World Conference On Lung Cancer 8/24/2015
NMT Pharmaceuticals Singapore Announces Signing Of Letter Of Intent With CAO Pharmacueticals USA In Licensing And Development Of Anti-Cancer Drug CZ-48 8/24/2015
RedHill Biopharma Ltd. (RDHL) Announces Peer-Reviewed Publication Demonstrating Therapeutic Potential Of ABC294640 (YELIVA(TM)) In Prostate Cancer 8/24/2015
Five Prime (FPRX) Announces Oral Presentation Of Initial Data From Ongoing Phase Ib Trial Of FP-1039/GSK3052230 In Squamous Non Small Cell Lung Cancer And Mesothelioma At World Conference On Lung Cancer 8/24/2015
Portage Biotech's Biohaven's Lead Drug Candidate Clears FDA Investigational New Drug Application (IND) Review And Clinical Studies To Begin 8/24/2015
Spotlight Innovation Subsidiary Celtic Biotech Prepares To Start Part 2 Of Phase I Intravenous Crotoxin Clinical Study 8/24/2015
Vaxart, Inc. Announces Lancet ID Publication Of Influenza Tablet Vaccine Phase 1 Results 8/24/2015
MMJ PhytoTech Ltd (ASX:MMJ) To Commence Phase 1 Clinical Study Late 2015 8/24/2015
HSRx Group's Acne Treatment Product In Clinical Trial, Aims To Rapidly Reduce Redness And Intensity Of Breakouts 8/24/2015
Cellectar Biosciences  (NVLT) Introduces Phospholipid Ether-Drug Conjugate (PDC) Platform For Targeted Delivery Of Chemotherapeutics 8/21/2015
PharmaMar Announces License Agreement With Specialised Therapeutics Australia Pty For APLIDIN (plitidepsin) In Oncology 8/20/2015
Advaxis, Inc. And MedImmune (AZN) Commence Enrollment In Phase I/II Study Of Axalimogene Filolisbac (ADXS-HPV) In Combination With Durvalumab (MEDI4736) For The Treatment Of HPV-Associated Cancers 8/20/2015
Biota Pharmaceuticals, Inc. (BOTA) Advances RSV Program With Commencement Of Dosing In Phase I Trial For Direct-Acting Antiviral BTA585 8/20/2015
BioLineRx Ltd. Reports Second Quarter 2015 Financial Results 8/20/2015
EnGeneIC Initiates Phase 1 Tailored-EDV Clinical Study In Solid Tumors 8/19/2015
Paradigm Announces Molecular Profiling Collaboration For Study of Altiratinib In Genomically Defined Cancer Patients 8/19/2015
SELLAS Life Sciences Expands And Strengthens Leadership Team 8/19/2015
Soligenix (SNGX) Receives Additional National Institute of Allergy And Infectious Diseases (NIAID) Funding To Advance Development Of Heat Stable Ricin Vaccine 8/19/2015
FDA Grants Qualified Infectious Disease Product (QIDP) Designation To VL-2397, Vical  (VICL)'s Antifungal Product Candidate 8/19/2015
Edge Therapeutics Reports Positive Top-Line Phase I/II NEWTON Trial Results Of EG-1962 In Aneurysmal Subarachnoid Hemorrhage 8/19/2015
EpicentRx Announces Publication Of Phase 1 Trial Results For The Anti-Cancer Agent, Rrx-001, In Lancet Oncology 8/19/2015
Kite Pharma (KITE) CEO Refutes Rumors of Death Associated with Experimental Cancer Drug 8/18/2015
TapImmune Inc. (TPIV) Completes Transfer of IND From The Mayo Clinic 8/18/2015
Arno Therapeutics Receives Authorization to Proceed With Modified Phase I/II Trial Evaluating Onapristone In Prostate Cancer 8/18/2015
Progressing Towards Clinical Trials: Kadimastem Proves Efficacy Of Its Unique ALS Treatment In Pre-Clinical Trials 8/18/2015
CytoDyn Release: First Self-Injectable HIV Antibody: 98% Success Rate In Phase 2b Clinical Trial, Could Be Commercial 8/18/2015
Deciphera Pharmaceuticals Announces Study Results For Altiratinib Demonstrating Inhibition Of Three Major Cancer-Promoting Pathways To Durably Block Tumor Growth And Invasion 8/18/2015
Pfenex (PFNX) Wins $143.5 Million Next-Gen Anthrax Vaccine Contract 8/17/2015
Summit Therapeutics Announces Phase Ib Modified Diet Clinical Trial Achieves Primary Objective In Duchenne Muscular Dystrophy 8/17/2015
DelMar Pharmaceuticals Receives Additional Non-Dilutive Funding From NRC-IRAP To Support Expanded Research Program With Lead Product Candidate VAL-083 8/17/2015
Amarantus BioSciences, Inc. Reports Second Quarter 2015 Financial Results And Business Overview 8/17/2015
Arno Therapeutics Reports Second Quarter 2015 Financial Results And Business Update 8/17/2015
Retrotope Announces Open Enrollment For Friedreich's Ataxia Clinical Trial 8/17/2015
3SBio Inc. (SSRX) Selected As A Constituent Of The Hang Seng Composite LargeCap & MidCap Index 8/17/2015
FDA Grants Fast Track Designation To ContraFect (CFRXU)'s CF-301, The First Of Its Lysins, Currently In Development For The Treatment Of Staph Aureus Infections, Including MRSA 8/17/2015
Pulmatrix Reports 2nd Quarter Results; Provides Update On Business & Development Pipeline 8/14/2015
Rush University Medical Center Release: Regenerating Nerve Tissue In Spinal Cord Injuries 8/14/2015
Bayer HealthCare (BAY) To Present Latest Research At The National Hemophilia Foundation Annual Meeting In Dallas 8/14/2015
Bellicum (BLCM) Provides Operational Update And Reports Financial Results For The Second Quarter Ended June 30, 2015 8/14/2015
Catabasis Pharmaceuticals, Inc. Reports Second Quarter 2015 Financial Results And Recent Corporate Highlights 8/14/2015
Proteon Therapeutics, Inc. (PRTO) Announces Top-Line Results From Phase I Study of Investigational Drug Vonapanitase in Patients With Symptomatic Peripheral Artery Disease 8/14/2015
Catabasis Pharmaceuticals, Inc. Announces Positive Top-line Phase 1 Data For Hypercholesterolemia Product Candidate CAT-2054 8/14/2015
Pfenex (PFNX) Reports Second Quarter 2015 Results And Provides Business Update 8/13/2015
Hua Medicine’s Diabetes Drug Shows Efficacy In Phase Ic Trial 8/13/2015
Immunovaccine Inc. Announces Financial Results For Quarter Ended June 30, 2015 8/13/2015
BioLineRx Ltd. To Report Second Quarter 2015 Results On August 20, 2015 8/13/2015
Johnson & Johnson Innovation (JNJ) Announces Collaboration On Immuno-Oncology Antibody ADC-1013 With Alligator Bioscience 8/12/2015
Tobira Therapeutics Inc. Reports Second Quarter 2015 Financial Results 8/12/2015
CMC Biologics Enters Into Agreement With The PATH Malaria Vaccine Initiative For Accelerated Development And Manufacturing Of Monoclonal Antibodies 8/12/2015
InSite Vision (ISV) Reports Second Quarter 2015 Financial Results 8/12/2015
Exelixis (EXEL) Announces Second Quarter 2015 Financial Results And Provides Corporate Update 8/12/2015
Dyax Corp. (DYAX) Provides Update On DX-2930 Clinical And Commercial Supply Initiatives 8/12/2015
Theravance Biopharma, Inc. Reports Second Quarter 2015 Financial Results And Provides Business Update 8/12/2015
Neuropore Therapies Commences Phase I Clinical Trials 8/12/2015
Oncoceutics Release: Analog Of ONC201 Selected As Clinical Development Candidate 8/12/2015
Cyclacel Pharmaceuticals, Inc. (CYCC) Reports Second Quarter 2015 Financial Results 8/12/2015
Cidara Therapeutics (CDTX) Reports Second Quarter 2015 Financial Results And Provides Corporate Update 8/12/2015
BioClin Therapeutics Initiates Phase 2 Clinical Trial Evaluating B-701 For Treatment Of Urothelial Cell Carcinoma 8/11/2015
Portage Biotech's Biohaven Raises $ 4.1 Million In First Tranche Of Private Placement. Portage Invests $ 2.5 Million 8/11/2015
Vitae Pharma (VTAE) Announces Initiation Of A Phase I Multiple Ascending Dose Study Of VTP-43742 In Autoimmune Disorders 8/11/2015
OncoMed Pharmaceuticals, Inc. (OMED) Announces Second Quarter 2015 Financial Results And Updates Demcizumab Phase Ib Non-Small Cell Lung Cancer Survival Data 8/11/2015
G1 Therapeutics Announces Initiation Of Two Phase Ib/IIa Trials Of CDK4/6 Inhibitor G1T28 In Small-Cell Lung Cancer 8/11/2015
Asterias Biotherapeutics Reports Second Quarter Results 8/11/2015
AXIM Biotech Announces Launch Of Clinical Trials On Medchew RX And Development Of Pharmaceutical-Grade Cannabis Chewing Gum 8/11/2015
Kite Pharma (KITE) Reports Second Quarter 2015 Financial Results 8/11/2015
Xenon Pharmaceuticals Inc. Reports Second Quarter 2015 Financial Results and Provides Corporate Update 8/11/2015
Stemline Therapeutics, Inc. (STML) Reports Second Quarter 2015 Financial Results 8/11/2015
Blueprint Medicines (BPMC) Reports Second Quarter 2015 Financial Results And Provides Business Update 8/11/2015
Clovis Oncology (CLVS) Enters into Clinical Trial Collaboration 8/11/2015
Ignyta (RXDX) Announces Second Quarter 2015 Company Highlights And Financial Results 8/11/2015
ContraFect (CFRXU) Provides Update On CF-301 Phase 1 Trial 8/11/2015
Synergy Pharma Reports Second Quarter And First Half 2015 Financial Results And Business Update 8/11/2015
BioTime (BTX) Reports Second Quarter 2015 Results And Recent Developments 8/11/2015
Trevena, Inc. (TRVN) Reports Second Quarter 2015 Financial Results And Provides A Corporate Update 8/11/2015
Catabasis Pharmaceuticals, Inc. To Present At The American Chemical Society National Conference 8/11/2015
Bio-Path Holdings, Inc. (BPTH) Reports Second Quarter 2015 Operational And Financial Results 8/11/2015
Rock Creek Pharmaceuticals Announces Targeting Of Dermatological Disease, Updated Clinical And Regulatory Strategy And Second Quarter Results 8/11/2015
ZIOPHARM Oncology (ZIOP.OB) Reports Second-Quarter 2015 Financial Results And Recent Activities 8/11/2015
Intec Pharma Ltd. Announces Closing of U.S. Initial Public Offering 8/10/2015
Aduro Biotech (ADRO) Completes Enrollment In Phase 1b Clinical Trial Of CRS-207 Immunotherapy For The Treatment Of Mesothelioma 8/10/2015
Portage Biotech Invests In Sentien Biotechnologies Inc. 8/10/2015
Regeneus (RGS.AX) (ASX:RGS) First Patient Treated In Progenza Stem Cell Trial For Knee Osteoarthritis 8/10/2015
NeuralStem Inc. Reports Second Quarter 2015 Financial Results 8/10/2015
Celsion Corporation (CLSN) Reports Second Quarter 2015 Financial Results And Provides Business Update 8/10/2015
Regen BioPharma Progresses In FDA Responses To dCellVax Clinical Trial Questions 8/10/2015
CEL-SCI (CVM) Reports Third Quarter Fiscal Year 2015 Financial Results 8/10/2015
Verastem, Inc. (VSTM) Reports Second Quarter 2015 Financial And Corporate Results 8/10/2015
Ariad (ARIA) Announces First Patient Treated In Phase 2 Dose-Ranging Optic Trial Of Iclusig (Ponatinib) 8/10/2015
Antibe Therapeutics Inc. (ATE.V) Announces Completion Of Phase I Studies Of ATB-346 And An Update On Its Validation Studies 8/10/2015
Pfizer (PFE), Bristol-Myers Squibb (BMY) Rev Up New Immune Treatment for Oncology Research 8/10/2015
Immune Design Corporation (IMDZ) And Merck & Co. (MRK) To Collaborate On Combination Trials Of Two Immune Design Immunotherapies With Merck's KEYTRUDA For Non-Hodgkin's Lymphoma And Melanoma 8/10/2015
MabVax Therapeutics Holdings Provides Corporate Update And Reports Second Quarter 2015 Financial Results 8/10/2015
KaloBios Pharmaceuticals, Inc. (KBIO) Reports Second Quarter Financial Results And Provides Clinical Update 8/10/2015
GlycoMimetics, Inc. (GLYC) Reports Second Quarter 2015 Results 8/7/2015
Mirati Therapeutics  (MRTX) Reports Second Quarter 2015 Financial Results And Provides Business Update 8/7/2015
GenVec Inc. (GNVC) Reports Second Quarter 2015 Financial Results 8/7/2015
Dicerna (DRNA) Announces Second Quarter 2015 Financial And Operational Results 8/7/2015
bluebird bio (BLUE) Reports Second Quarter 2015 Financial Results And Recent Operational Progress 8/7/2015
Cerulean Pharma Inc. (CERU) Reports Second Quarter 2015 Corporate Highlights And Financial Results 8/7/2015
La Jolla Pharma (LJPC) Announces Second Quarter 2015 Financial Results And Recent Corporate Progress 8/7/2015
Five Prime (FPRX) Reports Second Quarter 2015 Results And Provides Business Update 8/7/2015
StemCells (STEM) Reports Second Quarter 2015 Financial Results, Business Update And Clinical Program Highlights 8/7/2015
Ocata Therapeutics Provides Corporate Update For The Second Quarter Of 2015 8/7/2015
Heron (HRTX) Announces Second Quarter 2015 Financial Results And Recent Corporate Progress 8/7/2015
MabVax Therapeutics, Inc. And The Rockefeller University Enter Into A Collaborative Research Agreement 8/6/2015
Vtesse, Inc. Announces Preliminary Data From Ongoing Phase 1 Study Of VTS-270 For Treatment Of Niemann-Pick Disease Type C 8/6/2015
Nektar Therapeutics (NKTR) Reports Financial Results For The Second Quarter Of 2015 8/6/2015
Valor Biotherapeutics To Begin Phase 1 Clinical Study Of Novel Lymphoma Therapy 8/6/2015
Oncolytics Biotech Inc. (ONC.TO) Announces 2015 Second Quarter Results 8/6/2015
Agios (AGIO) Reports Second Quarter 2015 Financial Results And Provides Updates On Clinical Development Progress 8/6/2015
Ironwood (IRWD) Provides Second Quarter 2015 Investor Update 8/6/2015
Sarepta (SRPT) Announces Second Quarter 2015 Financial Results And Recent Corporate Developments 8/6/2015
Synta (SNTA) Reports Second Quarter 2015 Financial Results 8/6/2015
Acceleron Pharma Reports Second Quarter 2015 Financial And Operational Results 8/6/2015
Seres Therapeutics Reports Second Quarter 2015 Financial Results And Provides Business Update 8/6/2015
BIND Therapeutics (BIND) Reports Second Quarter 2015 Financial Results And Provides Corporate Update 8/6/2015
Infinity Pharmaceuticals Inc. (INFI) Provides Company Update And Reports Second Quarter 2015 Financial Results 8/6/2015
Genocea Biosciences Reports Second Quarter 2015 Financial Results 8/6/2015
Fate Therapeutics (FATE) Reports Second Quarter 2015 Financial Results 8/6/2015
MabVax Therapeutics, Inc. Issues Letter To Stockholders 8/5/2015
Bellicum (BLCM) Announces Patent Issued On Methods For Inducing Selective Apoptosis For Its Lead Product Candidate BPX-501 8/5/2015
Cold Genesys, Inc. Secures Series B Investment For Pivotal And Combo Immunotherapy Trials 8/5/2015
La Jolla Pharma (LJPC) Announces Exclusive Worldwide License Agreements Covering LJPC-30Sa And LJPC-30Sb 8/5/2015
Concert Pharmaceuticals, Inc. (CNCE) Reports Second Quarter 2015 Financial Results And Provides Company Update 8/5/2015
Kolltan Pharmaceuticals Inc. Appoints Ronald A. Peck, M.D., Chief Medical Officer And SVP, Clinical Development 8/5/2015
Pharmaxis (PXS.AX) And Synairgen plc Announce Research Collaboration To Develop LOXL2 Inhibitor For Pulmonary Fibrosis 8/5/2015
Arrowhead Research Corporation (ARWR) Reports Fiscal 2015 Third Quarter Financial Results 8/5/2015
Retrophin (RTRX) Reports Second Quarter 2015 Financial Results 8/5/2015
Hydra Biosciences, Inc. Appoints Leading Pulmonary Experts To Newly Created Medical Advisory Board 8/5/2015
bluebird bio (BLUE) Announces Participation At The 2015 Wedbush PacGrow Healthcare Conference 8/5/2015
Sunshine Biopharma, Inc. Announces That The Initial Manufacturing Sample Of Its Anticancer Compound Adva-27a Meets Biological Specifications Paving The Way For Clinical Trials 8/4/2015
DURECT Corporation (DRRX) Announces Second Quarter 2015 Financial Results And Update Of Programs 8/4/2015
Nivalis Therapeutics Reports Financial Results For The Second Quarter 2015 8/4/2015
BeiGene Co.,Ltd Receives Approval To Initiate Clinical Trials In China With BGB-283 For Solid Tumor Cancers 8/3/2015
Cidara Therapeutics (CDTX) Initiates Phase 1 Study Of Lead Antifungal Product Candidate CD101 IV 8/3/2015
Medivir (MVRBF) Announces That Janssen Pharmaceutical Has Started A Phase I Study To Evaluate The Effect Of Simeprevir And Odalasvir On AL-335 Pharmacokinetics 8/3/2015
Charleston Laboratories, Inc. Initiates Patient Enrollment In A Phase 1 Study Of Charleston's Second Product, CL-H1T 8/3/2015
Protalix Biotherapeutics, Inc. (PLX) Reports Positive Phase I Clinical Study Results For PRX-106 Oral Anti-TNF 8/3/2015
Daiichi Sankyo, Plexxikon Inc.'s Rare Disease Drug Shows Promise in Phase I Study 7/30/2015
Suzhou Connect Reports Positive Results For Trial Of Autoimmune Drug 7/30/2015
ViaCyte, Inc. (Formerly Known as Novocell, Inc.) Announces Second Clinical Trial Site At University of Alberta 7/30/2015
Kyowa Hakko Kirin And Bristol-Myers Squibb (BMY) Announce Immuno-Oncology Clinical Collaboration Studying Mogamulizumab And Opdivo (Nivolumab) In Advanced Solid Tumors In The U.S. 7/30/2015
GlaxoSmithKline (GSK) CEO Confident Investors Will Be Pleased With Pipeline on Nov. R&D Day 7/30/2015
Medivir (MVRBF) Announces Start Of A Phase I Clinical Trial Of The Nucleotide Polymerase Inhibitor AL-704 For Treatment Of Hepatitis C 7/29/2015
OncoMed Pharmaceuticals, Inc. (OMED) Initiates Phase I Clinical Trial For Anti-RSPO3 Antibody 7/28/2015
University of Colorado Cancer Center And Loxo Oncology (LOXO) Announce Publication That Provides Clinical Validation For LOXO-101 Against TRK Fusion Cancer 7/28/2015
Human Study Shows Remedy Pharmaceuticals, Inc.’ CIRARA Is Key To Preventing Brain Swelling In Stroke 7/28/2015
Moerae Initiates Lipopolysaccharide (LPS) Challenge Study Of Inhaled MMI-0100 For Pulmonary Disease Following Encouraging Safety And Tolerability Observed In Single Ascending Dose Phase 1 Study 7/28/2015
Embattled Vitae Pharma (VTAE) and Boehringer Ingelheim Relationship Takes Another Blow, Drops BACE Inhibitor Program for Alzheimer’s 7/27/2015
ZIOPHARM Oncology (ZIOP.OB) Announces Orphan Drug Designation For Ad-RTS-Hil-12 In The Treatment Of Malignant Glioma 7/27/2015
Inovio Pharmaceuticals (INO) Initiates Clinical Trial Of INO-5150 DNA Immunotherapy For Prostate Cancer 7/27/2015
Vaxin, Inc. First-in-Man Phase I Clinical Trial Initiated In Chronically Infected Hepatitis B Patients 7/27/2015
Cardiome Pharma Corp. (COM.TO) Partner Eddingpharm (Cayman) Inc. To Initiate BRINAVESS Phase I Study In China 7/24/2015
Encouraging Results Of AXON's Tau Vaccine Advance Alzheimer's Therapy 7/23/2015
Portage Biotech's Biohaven Announces IND Filing For Bhv-0223 For Phase 1 Clinical Testing 7/23/2015
Lpath (LPTN) Announces Plan To Begin Lpathomab Clinical Trial 7/23/2015
NeuralStem Inc. Release: US District Court Rules In Favor Of Neuralstem In Patent Infringement Case 7/23/2015
Sarepta (SRPT) Announces The New England Journal of Medicine Publication Of Phase I Clinical Data Of Marburg Drug Candidate, AVI-7288, Supporting Safety Of The Pmoplus Platform 7/23/2015
ANGLE plc Preliminary Results For The Year Ended 30 April 2015 7/23/2015
Biogen (BIIB) Presents New Data From Phase IB Study Of Investigational Alzheimer’s Disease Treatment Aducanumab (BIIB037) At Alzheimer’s Association International Conference 2015 7/22/2015



//-->